CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that the French regulatory agency for medical products, AFSSAPS, has published specifications for the INTERCEPT plasma system in the Official Journal. As a result of this publication, French blood centers are authorized to prepare and sell plasma treated with the INTERCEPT Blood System. While reimbursement pricing also needs to be established, the company understands that French blood centers may now purchase the plasma system in advance of the reimbursement decision.
